Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Lancet
M. DatooHalidou Tinto

Abstract

Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new candidate vaccine for safety and efficacy. In this double-blind, randomised, controlled, phase 2b trial, the low-dose circumsporozoite protein-based vaccine R21, with two different doses of adjuvant Matrix-M (MM), was given to children aged 5-17 months in Nanoro, Burkina Faso-a highly seasonal malaria transmission setting. Three vaccinations were administered at 4-week intervals before the malaria season, with a fourth dose 1 year later. All vaccines were administered intramuscularly into the thigh. Group 1 received 5 μg R21 plus 25 μg MM, group 2 received 5 μg R21 plus 50 μg MM, and group 3, the control group, received rabies vaccinations. Children were randomly assigned (1:1:1) to groups 1-3. An independent statistician generated a random allocation list, using block randomisation with variable block sizes, which was used to assign participants. Participants, their families, and the local study team were all masked to group allocation. Only the pharmac...Continue Reading

References

May 25, 2011·Expert Review of Vaccines·Jason A RegulesChristian F Ockenhouse
Oct 20, 2011·The New England Journal of Medicine·UNKNOWN RTS,S Clinical Trials PartnershipPreeti Vansadia
Nov 10, 2012·The New England Journal of Medicine·UNKNOWN RTS,S Clinical Trials PartnershipPreeti Vansadia
Aug 30, 2013·Expert Review of Vaccines·Karin Lövgren BengtssonLinda Stertman
Nov 19, 2013·Lancet·Vasee S MoorthyJean-Marie Okwo-Bele
Apr 28, 2016·MBio·Sabra L KleinPeter Aaby
Jun 30, 2016·The New England Journal of Medicine·Ally OlotuPhilip Bejon
Dec 13, 2016·Trends in Parasitology·Irene N NkumamaFaith H A Osier
Apr 20, 2017·Scientific Reports·Katharine A CollinsAdrian V S Hill
Apr 14, 2018·Malaria Journal·Hamtandi Magloire NatamaAnna Rosanas-Urgell
Sep 3, 2020·The New England Journal of Medicine·Cheryl KeechGregory M Glenn

❮ Previous
Next ❯

Citations

May 9, 2021·Lancet·Vasee Moorthy, Fred Binka
Jun 12, 2021·Nature Metabolism·Malcolm J McConville, Christian R Engwerda
Jun 28, 2021·Vaccine·Sylvester DassahMichael Theisen
Jul 2, 2021·Nature·Nana K Minkah, Stefan H I Kappe
Jul 4, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Thomas NyirendaMichael Makanga
Oct 13, 2021·Nature Microbiology·Irene N Nkumama, Faith H A Osier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.